Cancer

RSS

SuperGen updates progress of phase III rubitecan trials

Sep. 4, 2000

Arimidex approved by FDA as first-line therapy of breast cancer

Sep. 4, 2000

Cytogen and Northwest Biotherapeutics execute PSMA sublicense agreement

Sep. 4, 2000

Study results for Targretin in NSCLC support phase III program

Sep. 4, 2000

Vascular damaging agents reported by Angiogene

Sep. 1, 2000

RXR-selective ligands offer approach to tamoxifen-resistant tumors

Sep. 1, 2000

Novogen's lead anticancer compound continues to advance in clinical trials

Sep. 1, 2000

Cancer gene therapy with fusion molecule induces potent, selective apoptosis

Sep. 1, 2000

Aminobisphosphonates activate T-cells against multiple myeloma

Sep. 1, 2000

Matrix metalloproteinase inhibitors claimed by Aventis

Aug. 30, 2000